Targeting notch in prostate cancer - Combination is the key

Nature Reviews Urology

Volumn 11, Issue 7, 2014, Pages 419-

  Marignol, Laure ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DOCETAXEL; GAMMA SECRETASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH RECEPTOR;

CANCER RESISTANCE; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; IMMUNOSURVEILLANCE; LETTER; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; ANIMAL; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84904047880     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.110-c3     Document Type: Letter

References (15)

1. Marignol, L., Rivera-Figueroa, K., Lynch, T. & Hollywood, D. Hypoxia, notch signalling and prostate cancer. Nat. Rev. Urol. 10, 405-413 (2013).
2. Masuda, S. & Izpisua Belmonte, J. C. A recipe for targeted therapy. Nat. Rev. Urol. http://dx.doi.org/10.1038/nrurol.2013.110?c1.
3. Ranasinghe, W. K. B., Baldwin, G. S., Shulkes, A., Bolton, D. & Patel, O. Normoxic regulation of HIF?1? in prostate cancer. Nat. Rev. Urol. http://dx.doi.org/10.1038/nrurol.2013.110?c2.
4. Chalmers, A. J., Lakshman, M., Chan, N. & Bristow, R. G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin. Radiat. Oncol. 20, 274-281 (2010).
5. van Es, J. H. et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
6. Shih, Ie-M. & Wang, T.-L. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 67, 1879-1882 (2007).
7. Seruga, B., Ocana, A. & Tannock, I. F. Drug resistance in metastatic castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 8, 12-23 (2011).
8. Kelly, W. K. et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30, 1534-1540 (2012).
9. Tannock, I. F. et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 14, 760-768 (2013).
10. Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694-705 (2010).
11. Huang, Y. et al. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T?cell function and inhibits tumor growth. Cancer Res. 71, 6122-6131 (2011).
12. Nwabo Kamdje, A. H. et al. Notch?3 and Notch?4 signaling rescue from apoptosis human B?ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood 118, 380-389 (2011).
13. Arzate-Mejia, R. G., Valle-Garcia, D. & Recillas?Targa, F. Signaling epigenetics: novel insights on cell signaling and epigenetic regulation. IUBMB Life 63, 881-895 (2011).
14. Hemming, M. L., Elias, J. E., Gygi, S. P. & Selkoe, D. J. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 6, e257 (2008).
15. Paris, D. et al. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur. J. Pharmacol. 514, 1-15 (2005)